There are no approved peptides for menopause symptoms such as hot flashes. Hormone therapy is still the most effective treatment, and the two newest non-hormonal drugs, fezolinetant and elinzanetant, cut moderate to severe hot flashes by blocking receptors for neurokinin B, a brain peptide; the drugs themselves are pills, not peptides.[1][3][5] Peptide drugs do have a proven role after menopause for osteoporosis (teriparatide, abaloparatide) and obesity (semaglutide).[7][8][9]
Most peptides marketed to women in menopause, from kisspeptin to epitalon, have no menopause trials at all. This guide sorts what’s proven from what isn’t. See also our longevity peptides hub.
Evidence-graded table
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Hormone therapy (not a peptide) | FDA-approved for this use | Most effective treatment for hot flashes; prevents bone loss[1] | Approved | Not applicable |
| Fezolinetant (Veozah; blocks a peptide receptor) | FDA-approved for this use | Fewer, milder hot flashes vs placebo at 12 weeks[3] | Approved 2023; liver warning[4] | Not applicable |
| Elinzanetant (Lynkuet; blocks peptide receptors) | FDA-approved for this use | About 3 fewer hot flashes a day than placebo at 12 weeks[5] | Approved October 2025[6] | Not applicable |
| Teriparatide (Forteo) | FDA-approved for this use | New spine fractures 5% vs 14% on placebo[7] | Approved: postmenopausal osteoporosis | Teriparatide |
| Abaloparatide (Tymlos) | FDA-approved for this use | Fewer spine and non-spine fractures[8] | Approved: postmenopausal osteoporosis | Abaloparatide |
| Semaglutide (Wegovy) | FDA-approved (obesity, not menopause) | 14.9% average weight loss[9] | Approved: obesity | Semaglutide |
| Oxytocin (vaginal gel) | Small human studies | Mixed results for vaginal atrophy[10] | Not approved for this use | Oxytocin |
| Oxytocin (nasal) | Human RCTs | No better than placebo for sexual function[11] | Not approved for this use | Oxytocin |
| Kisspeptin-10 | No evidence for menopause | Not tested for menopause symptoms | Not approved; FDA safety-risk list[13] | Kisspeptin-10 |
| Epitalon | Animal or lab only | Telomerase activity in cultured cells[14] | Not approved | Epitalon |
Why hot flashes involve brain peptides
Deep in the brain, a cluster of nerve cells called KNDy neurons helps control body temperature. They are named for three peptides they release: kisspeptin, neurokinin B and dynorphin. Estrogen normally keeps these cells in check. When estrogen falls at menopause, neurokinin B signaling becomes overactive and the brain’s thermostat misfires, causing hot flashes.[4]
That discovery led to drugs that block the neurokinin B receptor (NK3), rather than drugs that add a peptide. This is a useful example of why “peptide” in marketing doesn’t always mean what people think.
Start with what works
Hormone therapy. Estrogen, with a progestogen if you have a uterus, remains the most effective treatment for hot flashes and night sweats and prevents bone loss. For healthy women under 60 or within 10 years of their last period, the Menopause Society says benefits generally outweigh risks.[1] Low-dose vaginal estrogen treats dryness and painful sex with minimal absorption.[1] Hormone therapy is not right for everyone; women with a history of breast cancer, blood clots, stroke or active liver disease generally need other options, and the decision should weigh age, time since menopause and personal risks.[1]
Non-hormonal options. For women who can’t or prefer not to take hormones, the Menopause Society’s 2023 statement recommends options including certain antidepressants and fezolinetant.[2]
- Fezolinetant (Veozah) is a daily pill. In SKYLIGHT 1, both doses reduced the frequency and severity of moderate to severe hot flashes compared with placebo at 4 and 12 weeks.[3] Its label carries a boxed warning for liver injury and requires liver blood tests before and during treatment.[4]
- Elinzanetant (Lynkuet) blocks both NK1 and NK3 receptors. In OASIS 1 and 2, it cut hot flashes by about 3 more per day than placebo at week 12.[5] FDA approved it on October 24, 2025.[6]
Sleep, mood and perimenopause
Night sweats are a leading cause of broken sleep in midlife. In OASIS 1 and 2, elinzanetant also improved sleep disturbances and menopause-related quality of life compared with placebo at week 12.[5] Peptides marketed directly for sleep, such as DSIP, have weak human evidence; our DSIP vs melatonin comparison explains why.
Symptoms often start in perimenopause, the years before periods stop, when hormone levels swing rather than fall steadily. Periods may become irregular, and pregnancy is still possible. That matters for treatment choices: the approved non-hormonal hot-flash drugs are indicated for hot flashes due to menopause and were studied in postmenopausal women.[4][6] Mood changes, anxiety and brain fog are also common in this phase; they deserve a proper evaluation, because depression and thyroid problems can look similar.
Bone: proven peptide drugs
Bone loss speeds up after menopause. For women with osteoporosis and high fracture risk, teriparatide reduced new spine fractures from 14% to 5%,[7] and abaloparatide reduced spine and non-spine fractures over 18 months.[8] These are daily injections for treatment, not prevention in women with normal bone density.
Weight and metabolism
Midlife weight gain often shifts toward the abdomen. For women who meet the criteria for obesity treatment, semaglutide produced 14.9% average weight loss in STEP 1.[9] Neither semaglutide nor tirzepatide is approved for menopause symptoms themselves. Strength training helps protect muscle and bone during weight loss.
Vaginal health and libido
Oxytocin gel has been tested for vaginal atrophy. A 2023 meta-analysis of 7 trials and 631 women found it improved clinician-rated atrophy but not painful sex, vaginal pH or cell maturation, and the authors called for larger trials.[10] Nasal oxytocin improved sexual function no more than placebo in a randomized crossover trial that included postmenopausal women.[11]
Bremelanotide (Vyleesi, the approved form of PT-141) is approved only for premenopausal women with low sexual desire.[12]
What’s unproven
- Kisspeptin: part of the hot-flash circuit, but never tested as a menopause treatment. FDA lists kisspeptin-10 among compounding substances that may present significant safety risks.[13]
- Epitalon and other “longevity” peptides: cell and animal data only.[14] See epitalon vs TA-65 and Khavinson peptide bioregulators.
- Growth hormone peptides marketed for menopause skin and sleep: no menopause trials.
Questions for your clinician
- Am I a good candidate for hormone therapy, and which form and dose?
- If not, would fezolinetant, elinzanetant or another non-hormonal option suit me, and what monitoring is needed?
- Should I have a bone density scan now?
- What is the safest treatment for vaginal dryness in my situation?
For more options by life stage, see our guide to the best peptides for women over 40.
